Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis
Dates
study started
completion around
Principal Investigator
by Edward Kim, MD, PhD (ucdavis)

Description

Summary

A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer

Official Title

A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer

Details

Keywords

Pancreatic Adenocarcinoma, Metastatic, Cancer, oncolytic virus, VCN-01, Gemcitabine, Nab-Paclitaxel, Adenocarcinoma, Paclitaxel

Eligibility

Locations

  • University of California - Davis Cancer Center
    Sacramento California 95817 United States
  • Hoag Memorial Hospital Presbyterian
    Newport Beach California 92663 United States

Lead Scientist at University of California Health

  • Edward Kim, MD, PhD (ucdavis)
    Associate Professor, MED: Int Med Hematology/Oncology, School of Medicine. Authored (or co-authored) 32 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Theriva Biologics SL
ID
NCT05673811
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 96 study participants
Last Updated